Australia markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6484-0.0191 (-2.86%)
At close: 04:00PM EDT
0.6599 +0.01 (+1.77%)
After hours: 07:47PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 120.50M
Enterprise value 100.58M
Trailing P/E N/A
Forward P/E 1.29
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.42
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.54
52-week change 3-42.65%
S&P500 52-week change 326.49%
52-week high 31.4000
52-week low 30.6000
50-day moving average 30.7700
200-day moving average 30.7701

Share statistics

Avg vol (3-month) 3976.45k
Avg vol (10-day) 31.34M
Shares outstanding 5180.52M
Implied shares outstanding 6185.84M
Float 8168.36M
% held by insiders 16.81%
% held by institutions 115.12%
Shares short (30 Apr 2024) 414.43M
Short ratio (30 Apr 2024) 410.99
Short % of float (30 Apr 2024) 48.58%
Short % of shares outstanding (30 Apr 2024) 47.99%
Shares short (prior month 28 Mar 2024) 412.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 309 June 2017
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 309 June 2017

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.08%
Return on equity (ttm)-42.15%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -39.11M
Net income avi to common (ttm)-37.35M
Diluted EPS (ttm)-0.2500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.56M
Total cash per share (mrq)0.07
Total debt (mrq)374.83k
Total debt/equity (mrq)0.47%
Current ratio (mrq)5.17
Book value per share (mrq)0.50

Cash flow statement

Operating cash flow (ttm)-30.3M
Levered free cash flow (ttm)-18.92M